Repository

Publications

Multimodal single-cell profiling reveals crosstalk between macrophages and stromal cells in poor prognostic cholangiocarcinoma patients

Heij L, Hayat S, Reichel K, Maryam S, O'Rourke CJ, Tan X, van den Braber M, Verhoeff J, Halder M, Peisker F, Wiltberger G, Bednarsch J, Heise D, Deierl JC, Lang SA, Ulmer F, Luedde T, Dahl E, Jonigk D, Nolting J, Sivakumar S, Siveke J, Vondran F, Rocha FG, Baba HA, Hartmann S, Andersen JB, Hobloss Z, Ghallab A, Hengstler JG, Vallejo JJG, Kramann R, Neumann U.
NPJ Precis Oncol. 2026 Jan 28;10(1):105. doi: 10.1038/s41698-026-01292-6
2026 
Result from  

A confidence-based, artificial intelligence pathology model for diagnosis of intrahepatic cholangiocarcinoma

A confidence-based, artificial intelligence pathology model for diagnosis of intrahepatic cholangiocarcinoma. Cheng Y, Azouzi N, Laurent-Bellue A, Guo Z, Chung T, Zeng Q, Ghodsifard A, Albrecht T, Roessler S, Boulagnon-Rombi C, Vij M, Rela M, Akpinar R, Augustin J, Bazille C, Xu S, Kong S, Lechapt-Zalcman E, Tournigand C, Kempf E, Brustia R, Pawlotsky JM, Braconi C, Caruso S, Ziol M, Goeppert B, Di Tommaso L, Park YN, Calderaro J.
Ann Oncol. 2026 Mar 4:S0923-7534(26)00074-8.
2026 
Result from  

Perioperative approaches for patients with biliary tract cancer

Zorigtbaatar A, Li Z, Magyar CTJ, Aceituno L, Saborowski A, Vogel A, Grant RC, O'Kane GM, Sapisochin G.
Nat Rev Clin Oncol. 2026 Mar 3. doi: 10.1038/s41571-026-01130-5
2026 
Result from  

Health-related quality of life in biliary tract cancer clinical trials. The current state and future directions

Cavka L, Edeline J, Lamarca A
ESMO . 24 February 2026 . doi: 10.1016/j.esmogo.2026.100301
2026 
Result from  
Funded by  

Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab

Camera S, Fornaro L, Rimini M, Persano M, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Salani F, Bozzarelli S, Corallo S, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Chiara P, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Melo Alvim C, Roque R, Farinea G, Genovesi V, De Rosa A, Lavacchi D, Lo Prinzi F, Passeri L, Ferrara M, Foti S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Tesini G, Esposito L, Casadio C, Himmelsbach V, Landriscina M, Ahcene Djaballah S, Bekaii-Saab T, Masi G, Vogel A, Lonardi S, Vivaldi C, Rimassa L, Casadei-Gardini A.
Target Oncol . 2026 Feb 27. doi: 10.1007/s11523-026-01200-9
2026 
Result from  
Join the Action
JOIN